Component

Human serum lithium concentration

Context-specific entity; species, compartment and exposure are stated on each claim.

5 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Dehydration can promote lithium retention and toxicity.

    Human volume depletion/dehydration → Human serum lithium concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Official prescribing information
    experimental_model
    Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06.
    limitations
    Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    Fluid loss can amplify exposure.
    primary_references
    Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 568–574

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. · source_derived_draft · unverified_draft

    ## lithium-dehydration Fluid loss can amplify exposure. Dehydration can promote lithium retention and toxicity. Model: Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. Limitations: Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows. Evidence access: Official prescribing information Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada
    Complete structured claim and evidence

  2. Completers in the 2026 trial had mean serum lithium 0.17 mEq/L, with substantial variability.

    Lithium carbonate → Human serum lithium concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary full text
    experimental_model
    Mean daily carbonate dose 195 mg; serum SD 0.13 mEq/L among completers.
    limitations
    Completer exposure is not the whole randomized population or a recommended target.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    The actual exposure matters when comparing trials.
    primary_references
    Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41770546/ · DOI 10.1001/jamaneurol.2026.0072
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 544–550

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Mean daily carbonate dose 195 mg; serum SD 0.13 mEq/L among completers. · source_derived_draft · unverified_draft

    ## lithium-mci-2026-exposure The actual exposure matters when comparing trials. Completers in the 2026 trial had mean serum lithium 0.17 mEq/L, with substantial variability. Model: Mean daily carbonate dose 195 mg; serum SD 0.13 mEq/L among completers. Limitations: Completer exposure is not the whole randomized population or a recommended target. Evidence access: Primary full text Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41770546/ · DOI 10.1001/jamaneurol.2026.0072
    Complete structured claim and evidence

  3. Indomethacin raised plasma lithium while lowering renal lithium clearance in seven studied people.

    Indomethacin → Human serum lithium concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Three psychiatric patients and four volunteers; approximately 31% mean clearance reduction.
    limitations
    Small historical study; magnitude is not universal for all NSAIDs.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    A medicine can raise lithium exposure by slowing its removal.
    primary_references
    Indomethacin increases plasma lithium. · 1979 · https://pubmed.ncbi.nlm.nih.gov/444956/ · DOI 10.1136/bmj.1.6171.1115
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 376–382

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Three psychiatric patients and four volunteers; approximately 31% mean clearance reduction. · source_derived_draft · unverified_draft

    ## lithium-nsaid-clearance A medicine can raise lithium exposure by slowing its removal. Indomethacin raised plasma lithium while lowering renal lithium clearance in seven studied people. Model: Three psychiatric patients and four volunteers; approximately 31% mean clearance reduction. Limitations: Small historical study; magnitude is not universal for all NSAIDs. Evidence access: Primary abstract Indomethacin increases plasma lithium. · 1979 · https://pubmed.ncbi.nlm.nih.gov/444956/ · DOI 10.1136/bmj.1.6171.1115
    Complete structured claim and evidence

  4. Renin–angiotensin-system antagonists can increase steady-state lithium concentrations.

    Renin–angiotensin-system antagonist exposure → Human serum lithium concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Official prescribing information
    experimental_model
    Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06.
    limitations
    Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    Blood-pressure medicines can change exposure.
    primary_references
    Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 584–590

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. · source_derived_draft · unverified_draft

    ## lithium-ras-interaction Blood-pressure medicines can change exposure. Renin–angiotensin-system antagonists can increase steady-state lithium concentrations. Model: Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. Limitations: Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows. Evidence access: Official prescribing information Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada
    Complete structured claim and evidence

  5. SGLT2 inhibitors may lower serum lithium.

    SGLT2 inhibitor exposure → Human serum lithium concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Official prescribing information
    experimental_model
    Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06.
    limitations
    Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows.
    nutrient_topic
    Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
    plain_language
    Not all renal drug interactions increase exposure.
    primary_references
    Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada

    Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 592–598

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. · source_derived_draft · unverified_draft

    ## lithium-sglt2-interaction Not all renal drug interactions increase exposure. SGLT2 inhibitors may lower serum lithium. Model: Official prescribing information, sections 5, 7 and 12; updated 2026-07-06, prescribing text revised 2023-06. Limitations: Regulatory clinical statement; not an experiment resolving a single molecular target. No dosing recommendation follows. Evidence access: Official prescribing information Lithium and lithium carbonate prescribing information; DailyMed set c84cce95-cfcb-4426-aac6-d2f48f946ada, updated July 6 2026; prescribing text revised June 2023 · 2026 · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84cce95-cfcb-4426-aac6-d2f48f946ada
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards